文献速递炎症性肠病

炎症性肠病诊疗的成本:如何实现可持续性

The Cost of Inflammatory Bowel Disease Care: How to Make it Sustainable.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-08-14

全球炎症性肠病(IBD)患病率上升,高收入地区人均年直接医疗费用平均为9000至12000美元,间接成本因缺勤、出勤主义等被低估。实现可持续性的策略包括早期使用生物制剂、在资源有限环境中关注成本效益、推广生物类似药,以及利用技术和患者报告结局的多学科团队。

要点

  • 高收入地区IBD人均年直接医疗费用平均为9000至12000美元。
  • 间接成本主要来自缺勤、出勤主义等生产力损失,其实际影响被低估。
  • 可持续策略包括早期生物制剂、生物类似药、多学科团队和技术应用。

核心结论

  • 应对IBD日益加重的经济负担需要综合策略,解决医疗差异、增加可负担治疗的可及性并促进卫生系统协作。
  • 采用创新策略可为所有IBD患者提供个体化、成本有效的诊疗,并确保更好的结局与可持续性。

研究设计与样本

  • 综述,探讨IBD当前与未来的诊疗成本及可持续策略。

主要发现

  • 高收入地区IBD人均年直接医疗费用平均为9000至12000美元,包括门诊、住院和药物。
  • 这些估计未充分涵盖疾病严重程度、可及性和区域卫生基础设施差异等因素。
  • 间接成本主要来自缺勤、出勤主义等生产力损失及其他无形成本,许多方面仍知之甚少,导致实际影响被低估。
  • 实现成本可持续性的挑战包括可及性差异、治疗可负担性和缺乏标准化的成本有效诊疗指南。

关键数值与推荐

  • 使IBD诊疗可持续的策略包括早期实施生物制剂治疗。
  • 在资源有限的环境中关注成本效益。
  • 促进生物类似药的采用以降低直接成本。
  • 利用技术和患者报告结局的多学科诊疗团队也有望降低直接和间接成本。

局限性

  • 直接费用估计未充分涵盖疾病严重程度、可及性和区域卫生基础设施差异等因素。
  • 间接成本的许多方面仍知之甚少,导致其实际影响被低估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The rising global prevalence of inflammatory bowel diseases (IBDs), such as Crohn's disease and ulcerative colitis, underscores the need to examine current and future IBD care costs. Direct health care expenses, including ambulatory visits, hospitalizations, and medications, are substantial, averaging $9,000 to $12,000 per person annually in high-income regions. However, these estimates do not fully account for factors such as disease severity, accessibility, and variability in health care infrastructure among regions. Indirect costs, predominantly stemming from loss in productivity due to absenteeism, presenteeism, and other intangible costs, further contribute to the financial burden of IBD. Despite efforts to quantify indirect costs, many aspects remain poorly understood, leading to an underestimation of their actual impact. Challenges to achieving cost sustainability include disparities in access, treatment affordability, and the absence of standardized cost-effective care guidelines. Strategies for making IBD care sustainable include early implementation of biologic therapies, focusing on cost-effectiveness in settings with limited resources, and promoting the uptake of biosimilars to reduce direct costs. Multidisciplinary care teams leveraging technology and patient-reported outcomes also hold promise in reducing both direct and indirect costs associated with IBD. Addressing the increasing financial burden of IBD requires a comprehensive approach that tackles disparities, enhances access to cost-effective therapeutics, and promotes collaborative efforts across health care systems. Embracing innovative strategies can pave the way for personalized, cost-effective care accessible to all individuals with IBD, ensuring better outcomes and sustainability.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Burisch J, Claytor J, Hernandez I, et al. The Cost of Inflammatory Bowel Disease Care: How to Make it Sustainable. Clin Gastroenterol Hepatol. 2024. PMID: 39151644. doi:10.1016/j.cgh.2024.06.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。